Pump'n'Dump Biotech is pleased to announce that it has regained all rights to its innovative Cure-All technology from BigBad Pharma. BigBad had previously licensed the technology in a ground-breaking deal worth up to $200 million in possible milestone payments to Pump'n'Dump if all 37 possible indications for Cure-All were eventually approved by the FDA.
This is a huge opportunity for Pump'n'Dump, said its CEO, Alvin Sleaze. This revolutionary technology, together with the confidence shown in us by our new institutional investors, Short'n'Run, should enable us to go far. Short'n'Run has just shown complete backing for our technology by investing $5 million in our new Class J Convertible Preferred. This new preferred is convertible into common at a variable rate, depending on our stock price.
“We expect Phase I trials of Cure-All to commence sometime next year in Myanmar,” added Mr. Sleaze. “By conducting overseas trials we will easily save enough to justify an additional long-range business jet to enable us to efficiently reach the remote area in which the trials are to be held.”
The other advantage of Myanmar is the ability to skip the animal toxicology studies and go straight to human studies. “After all, we expect to use this drug in humans, not animals,” said Pump'n'Dump's new Director of Research, Dr. Kevorkian.
Asked to comment on Pump'n'Dump's declining stock price, Mr. Sleaze noted that many small biotechs had declined in the last year, and that a conspiracy between market makers, short sellers and certain naysayers on some Internet bulletin boards had combined to depress the stock. “Now that we have regained all rights to Cure-All, we expect our stock price to rebound strongly,” added Mr. Sleaze confidently. “After certain consulting contracts have been awarded, we also expect our stock to be added to the VD model portfolio. This expression of confidence by the managers of one of biotech's best-performing portfolios should provide a further strong boost to the stock price.”
Happy Holidays to all! |
